Four legislative actions could ease the burden of high-cost prescription drugs—such as a $1,000-per-pill hepatitis C drug—on Medicare, the public, and commercial payers, says U.S. Rep. Henry Waxman.
The DC Circuit Court of Appeals rules that the Patient Protection and Affordable Care Act does not authorize the IRS to extend tax credits to those who bought health insurance on the federal marketplace. An hour later, the Fourth Circuit Court upholds the statute.
More News & Analysis
- Roundtable: Life After a Healthcare Organization Acquisition
- CVS Ramps Up Retail Clinics with Provider Affiliations
- As States Regulate Provider Competition, Common Threads Emerge
- Hospitals Seeking to Understand PPACA Impact Turn to Data